NO20061791L - Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin - Google Patents

Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Info

Publication number
NO20061791L
NO20061791L NO20061791A NO20061791A NO20061791L NO 20061791 L NO20061791 L NO 20061791L NO 20061791 A NO20061791 A NO 20061791A NO 20061791 A NO20061791 A NO 20061791A NO 20061791 L NO20061791 L NO 20061791L
Authority
NO
Norway
Prior art keywords
phenylsulfonyl
piperazin
quinoline
polymorphic form
cns
Prior art date
Application number
NO20061791A
Other languages
English (en)
Norwegian (no)
Inventor
Asa Elisabeth Gladwin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20061791L publication Critical patent/NO20061791L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20061791A 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin NO20061791L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322629.7A GB0322629D0 (en) 2003-09-26 2003-09-26 Novel compound
PCT/EP2004/010843 WO2005040124A1 (fr) 2003-09-26 2004-09-23 Nouveau compose

Publications (1)

Publication Number Publication Date
NO20061791L true NO20061791L (no) 2006-04-24

Family

ID=29286934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061791A NO20061791L (no) 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Country Status (23)

Country Link
US (1) US20070032504A1 (fr)
EP (1) EP1667975B1 (fr)
JP (1) JP2007506702A (fr)
CN (1) CN1856471A (fr)
AU (1) AU2004283805A1 (fr)
BR (1) BRPI0414678A (fr)
CA (1) CA2540022A1 (fr)
CO (1) CO5680402A2 (fr)
DE (1) DE602004010410T2 (fr)
DK (1) DK1667975T3 (fr)
ES (1) ES2297465T3 (fr)
GB (1) GB0322629D0 (fr)
HR (1) HRP20080055T3 (fr)
IL (1) IL174213A0 (fr)
IS (1) IS8399A (fr)
MA (1) MA28093A1 (fr)
MX (1) MXPA06003375A (fr)
NO (1) NO20061791L (fr)
PL (1) PL1667975T3 (fr)
PT (1) PT1667975E (fr)
RU (1) RU2355681C2 (fr)
WO (1) WO2005040124A1 (fr)
ZA (1) ZA200601453B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CA2521811A1 (fr) 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Composes contenant un haloalkyle utilise comme inhibiteurs de cysteine protease
JP2008542328A (ja) 2005-06-02 2008-11-27 エフ.ホフマン−ラ ロシュ アーゲー Gaba−bエンハンサーとしての3−メタンスルホニルキノリン
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
EP2120950B1 (fr) * 2007-03-21 2012-07-04 Glaxo Group Limited Utilisation de derives quinoleines pour le traitement de la douleur
EP2254564A1 (fr) * 2007-12-12 2010-12-01 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
WO2017202206A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé quinoléine substitué et composition pharmaceutique correspondante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
AU2004283805A1 (en) 2005-05-06
EP1667975A1 (fr) 2006-06-14
RU2355681C2 (ru) 2009-05-20
DE602004010410T2 (de) 2008-10-16
RU2006114024A (ru) 2007-11-10
HRP20080055T3 (en) 2008-02-29
CO5680402A2 (es) 2006-09-29
WO2005040124A1 (fr) 2005-05-06
GB0322629D0 (en) 2003-10-29
CN1856471A (zh) 2006-11-01
IS8399A (is) 2006-04-05
IL174213A0 (en) 2006-08-01
US20070032504A1 (en) 2007-02-08
PL1667975T3 (pl) 2008-04-30
CA2540022A1 (fr) 2005-05-06
ES2297465T3 (es) 2008-05-01
MXPA06003375A (es) 2006-06-08
BRPI0414678A (pt) 2006-11-28
ZA200601453B (en) 2007-04-25
EP1667975B1 (fr) 2007-11-28
HK1094190A1 (en) 2007-03-23
PT1667975E (pt) 2008-02-29
MA28093A1 (fr) 2006-08-01
DE602004010410D1 (en) 2008-01-10
JP2007506702A (ja) 2007-03-22
DK1667975T3 (da) 2008-04-14

Similar Documents

Publication Publication Date Title
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
EA200801372A1 (ru) Способы получения замещенных пиримидинов
EA200501274A1 (ru) Пиразолы и способы их получения и применения
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
NO20075809L (no) DNA-PK inhibitorer
TW200510317A (en) Caspase inhibitors and uses thereof
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
SE0301368D0 (sv) Chemical compounds
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
WO2004043379A3 (fr) Composes chimiques
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
GB0322510D0 (en) Novel compounds
SE0300850D0 (sv) Chemical compounds
DE60329326D1 (de) Tace inhibitoren
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
SE0200844D0 (sv) Chemical compounds
SE0200843D0 (sv) Chemical compounds
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
NO20051146L (no) Fremgangsmate for fremstilling av mellomprodukter nyttige for fremstilling av tubulininhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application